A Double-masked, Randomized, Placebo-controlled,Pilot Study of Diquafosol Tetrasodium in Subjects Following Photorefractive Keratectomy (PRK)

NCT01381731 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

14

Enrollment

INDUSTRY

Sponsor class

Conditions

Photorefractive Keratectomy

Interventions

DRUG: diquafosol tetrasodium ophthalmic solution 2%
DRUG: placebo

Sponsor

Merck Sharp & Dohme LLC